• Druker, B.J. (2002) STI571 (Gleevec) as a paradigm for cancer therapy. Trends in Molecular Medicine, 8, s14s18.
  • Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N. & Sawyers, C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876880.
  • Gorre, M.E., Ellwood-Yen, K., Chiosis, G., Rosen, N. & Sawyers, C.L. (2002) BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukaemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood, 100, 30413044.
  • Hochhaus, A., Kreil, S., Corbin, A.S., La Rosee, P., Muller, M.C., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N.C., Berger, U., Gschaidmeier, H., Druker, B.J. & Hehlmann, R. (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 16, 21902196.
  • Sawyers, C.L., Hochhaus, A., Feldman, E., Goldman, J.M., Miller, C.B., Ottmann, O.G., Schiffer, C.A., Talpaz, M., Guilhot, F., Deininger, M.W., Fischer, T., O'Brien, S.G., Stone, R.M., Gambacorti-Passerini, C.B., Russell, N.H., Reiffers, J.J., Shea, T.C., Chapuis, B., Coutre, S., Tura, S., Morra, E., Larson, R.A., Saven, A., Peschel, C., Gratwohl, A., Mandelli, F., Ben-Am, M., Gathmann, I., Capdeville, R., Paquette, R.L. & Druker, B.J. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukaemia in myeloid blast crisis: results of a phase II study. Blood, 99, 35303539.
  • Topaly, J., Zeller, W.J. & Fruehauf, S. (2001) Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukaemia cells. Leukemia, 15, 342347.